Influence of dietary Saccharomyces cerevisiae fermentation product on markers of inflammation and cartilage metabolism in young exercising horses challenged with intra-articular lipopolysaccharide.
Abstract: The objective was to evaluate dietary fermentation product (SCFP) on joint inflammation and cartilage metabolism in exercising yearlings challenged with intra-articular lipopolysaccharide (LPS), hypothesizing dietary SCFP (TruEquineC, Diamond V Mills, Inc.) would ameliorate joint inflammation and increase cartilage metabolism. Thirty Quarter Horse yearlings were stratified by bodyweight (BW), age, sex, and randomly assigned to dietary treatments (n = 10/treatment): control (0), 46, or 92 mg/kg BW/d SCFP. Treatments were top-dressed to 1% BW/d concentrate void of added microbials. Horses were stalled (3.6 m × 7.3 m), offered ad libitum Coastal bermudagrass hay, and exercised 30 min/d, 5 d/wk. On days 0, 21, 42, and 56, wither height, hip height, heart girth, body length, body condition scores (BCS), and BW were recorded. On day 46, one radial carpal joint received 0.8 mL of a 0.5 ng LPS solution or sterile lactated Ringer's solution (LRS) in the contralateral joint. Synovial fluid was collected pre- (0) and 6, 12, 24, and 336 hours post-injection and analyzed for prostaglandin E (PGE), carboxypropeptide of type II collagen (CPII), and collagenase cleavage neopeptide (C2C) via commercial ELISA, and chemokines (CCL2, and CCL11) and cytokines (TNF and IL-10) via multiplex platform. Rectal temperature (RT), heart rate (HR), respiration rate (RR), and carpal circumference (CC) were recorded prior to arthrocentesis. Data were analyzed using PROC MIXED of SAS. By day 56, growth parameters increased ( < 0.01), BCS did not change ( = 0.39), and BW had a treatment × d interaction ( = 0.02) where control tended to be heavier than 92 mg/kg BW on day 56 ( = 0.07). Clinical parameters (RT, HR, RR, CC) were uninfluenced by diet ( ≥ 0.29) but varied over time ( ≤ 0.03). Treatments did not influence cartilage metabolism (CPII, C2C, and CPII:C2C) ( ≥ 0.46) or logPGE, logCCL2, CCL11, or logIL-10 ( ≥ 0.23). There was a treatment × h interaction for CCL11 ( = 0.04) where control was greater than SCFP groups at h 6. LogIL-10 had a treatment × h interaction where 46 mg/kg BW was lower than control and 92 mg/kg BW at h 12 ( = 0.05). There was a main effect of treatment for TNF ( = 0.04) where 92 mg/kg BW was lower than 46 mg/kg BW and tended to be lower than control. Results indicate that SCFP didn't influence cartilage metabolism or PGE, though SCFP may ameliorate inflammatory cytokines and chemokines following an acute, intra-articular insult.
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
This study examined the effects of a dietary yeast fermentation product on joint inflammation and cartilage metabolism in young, exercising horses, suggesting that the product could possibly reduce joint inflammation and improve cartilage health.
Overview of the Study
With the main objective to study the effect of dietary Saccharomyces cerevisiae fermentation product (SCFP) on joint inflammation and cartilage metabolism, this study was carried out on thirty Quarter Horse yearlings.
The horses were bifurcated into three groups based on their body weight, and each group was assigned a different treatment level of SCFP (0, 46, or 92 mg/kg BW/d SCFP).
All horses were kept in stalls, fed Coastal bermudagrass hay, and exercised for 30 minutes per day, five days a week.
Various observations such as the horses’ height, body condition, heart girth, body length, and body weight were recorded on specified days throughout the study duration.
Further Procedures and Results
On day 46 of the experiment, a designated joint (radial carpal) of each horse was injected with either a Lipopolysaccharide (LPS) solution or sterile lactated Ringer’s solution (LRS) for comparison. Subsequently, synovial fluid samples were analysed for signs of inflammation and cartilage health.
By day 56, all initial growth parameters increased, but body condition scores remained unchanged. However, the body weight of horses in the control group was found to be higher than that of horses in the 92 mg/kg BW/d SCFP group.
There were no substantial changes noted in clinical parameters like heart rate, respiration rate, or carpal circumference due to diet variances. However, there were fluctuations in these observations over time.
Statistical analysis also revealed that the treatment did not impact cartilage metabolism, or the level of Prostaglandin E (PGE), a potent inflammatory mediator. However, there was a notable impact of treatment on certain inflammatory cytokines and chemokines after the LPS injection.
The group that received 92 mg/kg BW/d SCFP had lower levels of Tumor Necrosis Factor (TNF), an inflammatory cytokine, when compared to the other two groups.
Conclusion of the Study
The research concludes that although the SCFP did not influence cartilage metabolism or PGE, it may have an anti-inflammatory effect on the cytokines and chemokines after an acute, intra-articular insult.
This suggests a potential therapeutic use of SCFP for counteracting acute joint inflammation in horses due to external insults.
Cite This Article
APA
Moore GE, Leatherwood JL, Glass KG, Arnold CE, Paris BL, Carter MM, George JM, Fontenot AB, Martinez RE, Franklin MA, Norton SA, Bradbery AN, Wickersham TA.
(2025).
Influence of dietary Saccharomyces cerevisiae fermentation product on markers of inflammation and cartilage metabolism in young exercising horses challenged with intra-articular lipopolysaccharide.
Transl Anim Sci, 9, txaf042.
https://doi.org/10.1093/tas/txaf042
Bakker MF, Verstappen SM, Welsing PM, Jacobs JW, Jahangier ZN, Van Der Veen MJ, Bijlsma JW, Lafeber FP. The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial. Arthritis Res. Ther. 13:R70.
Brouwers H, Von Hegedus JH, Linden EVD, Mahdad R, Kloppenburg M, Toes R, Giera M, Ioan-Facsinay A. Hyaluronidase treatment of synovial fluid is required for accurate detection of inflammatory cells and soluble mediators. Arthritis Res. Ther. 24:18.
Evans M, Reeves S, Robinson LE. A dried yeast fermentate prevents and reduces inflammation in two separate experimental immune models. Evid. Based Complement. Alternat. Med. 2012:973041.
Frisbie DD, McIlwraith CW, De Grauw JC. Synovial fluid and serum biomarkers. Joint disease in the horse p. 179–191.
Ganda E, Chakrabarti A, Sardi MI, Tench M, Kozlowicz BK, Norton SA, Warren LK, Khafipour E. Saccharomyces cerevisiae fermentation product improves robustness of equine gut microbiome upon stress. Front. Vet. Sci. 10:1134092.
Hand TW, Vujkovic-Cvijin I, Ridaura VK, Belkaid Y. Linking the microbiota, chronic disease and the immune system. Trends Endocrinol. Metab. 27:831–843.
Hankittichai P, Buacheen P, Pitchakarn P, Na Takuathung M, Wikan N, Smith DR, Potikanond S, Nimlamool W. Artocarpus lakoocha extract inhibits lps-induced inflammatory response in raw 264.7 macrophage cells. Int. J. Mol. Sci. 21:1355.
Hog P, Kuntschar S, Rappl P, Huard A, Weigert A, Brüne B, Schmid T. Prostaglandin e2 boosts the hyaluronan-mediated increase in inflammatory response to lipopolysaccharide by enhancing lyve1 expression. Biology 12:1441.
Hsu YH, Hsieh MS, Liang YC, Li CY, Sheu MT, Chou DT, Chen TF, Chen CH. Production of the chemokine eotaxin-1 in osteoarthritis and its role in cartilage degradation. J. Cell. Biochem. 93:929–939.
Lin CY, Wang WH, Chen SH, Chang YW, Hung LC, Chen CY, Chen YH. Lipopolysaccharide-induced nitric oxide, prostaglandin e2, and cytokine production of mouse and human macrophages are suppressed by pheophytin-b. Int. J. Mol. Sci. 18:2637.
Lucia JL, Coverdale JA, Arnold CE, Winsco KN. Influence of an intra-articular lipopolysaccharide challenge on markers of inflammation and cartilage metabolism in young horses1. J. Anim. Sci. 91:2693–2699.
Meehan RT, Regan EA, Hoffman ED, Wolf ML, Gill MT, Crooks JL, Parmar PJ, Scheuring RA, Hill JC, Pacheco KA. Synovial fluid cytokines, chemokines and mmp levels in osteoarthritis patients with knee pain display a profile similar to many rheumatoid arthritis patients. J. Clin. Med. 10:5027.
Molnar V, Matišić V, Kodvanj I, Bjelica R, Jeleč Z, Hudetz D, Rod E, Čukelj F, Vrdoljak T, Vidović D. Cytokines and chemokines involved in osteoarthritis pathogenesis. Int. J. Mol. Sci. 22:9208.
Nelson F, Dahlberg L, Laverty S, Reiner A, Pidoux I, Ionescu M, Fraser GL, Brooks E, Tanzer M, Rosenberg LC. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J. Clin. Invest. 102:2115–2125.
Schott EM, Farnsworth CW, Grier A, Lillis JA, Soniwala S, Dadourian GH, Bell RD, Doolittle ML, Villani DA, Awad H. Targeting the gut microbiome to treat the osteoarthritis of obesity. JCI Insight 3:e95997.
Shinmei M, Ito K, Matsuyama S, Yoshihara Y, Matsuzawa K. Joint fluid carboxy-terminal type II procollagen peptide as a marker of cartilage collagen biosynthesis. Osteoarthritis Cartilage 1:121–128.
Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther. Adv. Musculoskelet. Dis. 5:77–94.
Wiertsema SP, Van Bergenhenegouwen J, Garssen J, Knippels LMJ. The interplay between the gut microbiome and the immune system in the context of infectious diseases throughout life and the role of nutrition in optimizing treatment strategies. Nutrients 13:886.